In silico analysis of the supposed absence of therapeutic synergism in the association of hydroxychloroquine and azithromycin in COVID-19




ACE2; Azithromycin; CD147; COVID-19; Hydroxychloroquine; Molecular Docking Simulation.


A associação terapêutica entre hidroxicloroquina (HCQ) e azitromicina (AZI) foi considerada como terapia para COVID-19, no entanto, não está claro se ocorre uma ação sinérgica. Para melhor compreender esta associação terapêutica, este estudo teve como objetivo analisar a interação do HCQ e AZI com receptores humanos in silico.. A análise foi realizada por simulação de docking molecular. As interações químicas do HCQ e AZI com prováveis ​​receptores no organismo humano, ACE2 e CD147, foram analisadas no software AutoDock Vina e os resultados analisados ​​no software PyMol. Os conformadores HCQ-ACE2 e AZI-CD147 foram formados com energia de afinidade significativa de -7,0 Kcal / mol e -7,8 Kcal / mol, respectivamente. Apesar da interação entre HCQ e ACE2 poder prevenir a invasão das células pelo vírus, essa interação pode levar a efeitos colaterais graves. Por sua vez, a interação AZI-CD147 também pode atuar impedindo a entrada do vírus nas células. Além disso, de acordo com o in silicodados, a interação AZI-CD147 ocorreria de forma mais eficaz, o que leva a crer que a ação terapêutica do HCQ no COVID-19 não é tão relevante quanto a ação do AZI e não haveria sinergismo.


Beigelman, A. et al. (2015). Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. Journal of Allergy and Clinical Immunology, 135(5), 1171-1178. Retrieved from

Beigelman, A. et al. (2010). Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respiratory research, 11(90), 1-11. Retrieved from

Bourgonje, A. R. et al (2020). Angiotensin‐converting enzyme‐2 (ACE2), SARS‐CoV‐2 and pathophysiology of coronavirus disease 2019 (COVID‐19). The Journal of Pathology, 251(3), 228-248. Retrieved from

Breuer, O., & Schultz, A. (2018). Side effects of medications used to treat childhood interstitial lung disease. Paediatric Respiratory Reviews, 28, 68-79. Retrieved from

Brufsky, A. (2020). Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic. Journal of Medical Virology, 92(7), 770-775. Retrieved from

Cancio, M. et al (2020). Emerging Trends in COVID-19 Treatment: Learning from Inflammatory Conditions Associated with Cellular Therapies. Cytotherapy. Retrieved from

CD147, a New Target of SARS-CoV-2 Invasion - CUSABIO. (2020). Retrieved from

Chen, Z. et al (2005). Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus. The Journal of infectious diseases, 191(5), 755-760. Retrieved from

Chico, R. M., & Chandramohan, D. (2011). Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert opinion on drug metabolism & toxicology, 7(9), 1153-1167. Retrieved from

Chorin, E. et al (2020). The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nature Medicine, 26(6), 807-808. Retrieved from

Cooper, R. G., & Magwere, T. (2008). Chloroquine: novel uses & manifestations. Indian Journal of Medical Research, 127(4), 305-316. Retrieved from

Coronavirus Update (Live): 43,099,164 Cases and 1,156,596 Deaths from COVID-19 Virus Pandemic – Worldometer. (2020). Retrieved from

Crosnier, C. et al (2011). Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature, 480(7378), 534-537. Retrieved from

de Souza Oliveira, E., Matos, M. F., Cavalcante, O. S. S., & de Morais, A. C. L. N. (2020). Off label use of antimalarials in covid-19 patients. Research, Society and Development, 9(6), 168963517. Retrieved from

Epidemiology Working Group for NCIP Epidemic Response. (2020). The epidemiological characteristics of na outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua liu xing bing xue za zhi, 41(2), 145-151. Retrieved from

Equi, A., Balfour-Lynn, I. M., Bush, A., & Rosenthal, M. (2002). Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. The Lancet, 360(9338), 978-984. Retrieved from

García, L. F. (2020). Immune response, inflammation, and the clinical spectrum of COVID-19. Frontiers in immunology, 11, 4-8. Retrieved from

Gautret, P. et al (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 105949. Retrieved from

Gautret, P. et al (2020). Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel medicine and infectious disease, 101663. Retrieved from

Gielen, V., Johnston, S. L., & Edwards, M. R. (2010). Azithromycin induces anti-viral responses in bronchial epithelial cells. European Respiratory Journal, 36(3), 646-654. Retrieved from

Jain, A., & Doyle, D. J. (2020). Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Medicine, 46, 1494-1495. Retrieved from

Kim, J. Y., Kim, W. J., Kim, H., Suk, K., & Lee, W. H. (2009). The stimulation of CD147 induces MMP-9 expression through ERK and NF-κB in macrophages: implication for atherosclerosis. Immune network, 9(3), 90-97. Retrieved from

Kuo, C. H., Lee, M. S., Kuo, H. F., Lin, Y. C., & Hung, C. H. (2019). Azithromycin suppresses Th1-and Th2-related chemokines IP-10/MDC in human monocytic cell line. Journal of Microbiology, Immunology and Infection, 52(6), 872-879. Retrieved from

Lima, C. M. A. D. O. (2020). Information about the new coronavirus disease (COVID-19). Radiologia Brasileira, 53(2), V-VI. Retrieved from

Liu, J. et al (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery, 6(1), 1-4. Retrieved from

Marmor, M. F., Kellner, U., Lai, T. Y., Melles, R. B., & Mieler, W. F. (2016). Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology, 123(6), 1386-1394. Retrieved from

Morris GM, Lim-Wilby M. Molecular Docking. In: Methods in Molecular Biology [Internet]. 2008. p. 365–82. Retrieved from

Perlman, S. (2020). Another decade, another coronavirus. The New England Journal of Medicine, 382, 760-762. Retrieved from

PyMol. (2017). The PyMol Molecular Graphics System, Version 2.0. Retrieved from

Vellano, P. O., & Paiva, M. J. M. (2020). O uso de antimicrobiano na COVID-19 e as infecções: o que sabemos. Research, Society and Development, 9(9), 1–18. Retrieved from

Raschka, S. (2014). Molecular docking, estimating free energies of binding, and AutoDock’s semi‐empirical force field. Retrieved from

Roberts, W. C., & High, S. T. (1999). The heart in systemic lupus erythematosus. Current problems in cardiology, 24(1), 1-56. Retrieved from

Roncon, L., Zuin, M., Rigatelli, G., & Zuliani, G. (2020). Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. Journal of Clinical Virology, 104354. Retrieved from

Rosenberg, E. S. et al (2020). Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. Jama, 323(24), 2493-2502. Retrieved from

Shityakov, S., & Förster, C. (2014). In silico predictive model to determine vector-mediated transport properties for the blood–brain barrier choline transporter. Advances and applications in bioinformatics and chemistry: AABC, 7, 23-36. Retrieved from

Shukla, A. M., Archibald, L. K., Shukla, A. W., Mehta, H. J., & Cherabuddi, K. (2020). Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs in Context, 9, 1-8. Retrieved from

Silhol, F., Sarlon, G., Deharo, J. C., & Vaïsse, B. (2020). Downregulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system?. Hypertension Research, 43, 854-856. Retrieved from

South, A. M., Diz, D. I., & Chappell, M. C. (2020). COVID-19, ACE2, and the cardiovascular consequences. American Journal of Physiology-Heart and Circulatory Physiology. Retrieved from

Sprague, H. B. (1946). The effects of malaria on the heart. American heart journal, 31(4), 426-430. Retrieved from

Tran, D. H. et al(2019). Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09 virus infection by interfering with virus internalization process. The Journal of antibiotics, 72(10), 759-768. Retrieved from

Trott, O. & Olson, A. J. Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Comput. Chem, 31(2), 455-461. Retrieved from

Ulrich, H., & Pillat, M. M. (2020). CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Reviews and Reports, 16, 434-440. Retrieved from

Vellano, P. O., & Paiva, M. J. M. (2020). O uso de antimicrobiano na COVID-19 e as infecções: o que sabemos. Research, Society and Development, 9(9), 1–18. Retrieved from

Wang, K. et al (2020). SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. BioRxiv. Retrieved from

WHO announces COVID-19 outbreak a pandemic. (2020). Retrieved from

Wilson, D. W. et al (2015). Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum. BMC biology, 13(1), 52. Retrieved from

Xiao, L., Sakagami, H., & Miwa, N. (2020). ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?. Viruses, 12(5), 491. Retrieved from

Zhou, F. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 395, 1054-1062. Retrieved from

Zimmermann, P., Ziesenitz, V. C., Curtis, N., & Ritz, N. (2018). The immunomodulatory effects of macrolides—a systematic review of the underlying mechanisms. Frontiers in immunology, 9(302), 1-14. Retrieved from



How to Cite

FERNANDES, B.; PINTO, L. G.; SILVA, Ériky F. G.; MARCUSSI , A. D. F. .; GROTO, A. D.; TEIXEIRA, K. N. . In silico analysis of the supposed absence of therapeutic synergism in the association of hydroxychloroquine and azithromycin in COVID-19. Research, Society and Development, [S. l.], v. 9, n. 11, p. e2249119712, 2020. DOI: 10.33448/rsd-v9i11.9712. Disponível em: Acesso em: 6 may. 2021.



Health Sciences